ZURICH (Reuters) - A Novartis executive said the Swiss company's heart failure medicine Entresto could be used more widely in future, potentially making it a blockbuster drug with revenue potential of ...

Cardiovascular med Entresto’s blockbuster turn in 2018 was a long time coming for Novartis, which held on to a $5 billion vision for the drug even as its launch lagged. But those dreams took another ...

Novartis is banking on a broader label to expand the reach of its blockbuster heart med Entresto, but in patients who've suffered prior heart attacks, the drug just hit a setback. In the phase 3 ...

The rate of cardiovascular death for Entresto patients was 5.9% versus ramipril's 6.7%. There was a 6% rate of heart failure hospitalizations in the Entresto arm, versus 6.9% in the ACE inhibitor ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign marks Novartis' Institutes for Biomedical Research in Cambridge ZURICH (Reuters) - Novartis' bid to pump up sales of its ...

Novartis last year launched an unbranded campaign called Understanding Heart Failure. Novartis’ new heart-failure drug Entresto generated $21 million in sales in 2015, and the company attributed the ...

ZURICH (Reuters) - Novartis' bid to pump up sales of its Entresto heart failure medicine beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel recommended it be used to treat ...

ZURICH — Novartis’ bid to pump up sales of its Entresto heart failure medicine beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel recommended it be used to treat a ...

ZURICH, Dec 16 (Reuters) - Novartis' (NOVN.S), opens new tab bid to pump up sales of its Entresto heart failure medicine beyond $5 billion annually got a boost when a U.S. Food and Drug advisory panel ...